Source comparison
SS-31 vs MOTS-C: Safety Profile and Adverse Event Data
The SS-31 vs MOTS-C safety comparison is informed by clinical trial data for SS-31 and preclinical data for MOTS-C. In the SPARCL and MMPOWER trials of SS-31 (elamipretide), the most commonly reported adverse events were injection site reactions (erythema, ind
This comparison does not assign a generated winner or score.
- The SS-31 vs MOTS-C safety comparison is informed by clinical trial data for SS-31 and preclinical data for MOTS-C. In the SPARCL and MMPOWER trials of SS-31 (elamipretide), the most commonly reported adverse events were injection site reactions (erythema, induration) in approximately 33% of participants, which were predominantly mild-to-moderate.
- No serious cardiac adverse events attributable to the compound were reported across combined trial populations. No dose-limiting toxicity was identified at doses up to 40 mg/day subcutaneous in Phase II studies. The compound did not affect QTc interval or standard hematological parameters, supporting a generally favorable safety profile at therapeutic research doses.
- For MOTS-C, preclinical safety data from rodent and primate studies indicates a similarly benign profile. Doses up to 20 mg/kg in rodent studies produced no observable toxicity in standard organ panels (liver enzymes, kidney function, complete blood count).
- No immunogenicity signals were detected in multi-week dosing protocols, consistent with MOTS-C being an endogenous peptide recognized by innate immune tolerance mechanisms. Researchers comparing SS-31 vs MOTS-C should note that MOTS-C lacks human clinical trial data, making direct safety comparisons premature — but the endogenous nature of MOTS-C and its favorable preclinical profile make it a compelling subject for future investigational work. The peptide side effects guide provides additional context for understanding research compound safety considerations.